People
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
The new CEO of Freenome has a talent for “making his own weather.” That’s a phrase he heard often growing up in Rapid City, South Dakota and, when applied to his life and career, comes down to assessing himself accurately and looking for opportunities to contribute.
Moderna CEO Stéphane Bancel believes the promise of mRNA vaccines is so great they will become a disruptive force in preventing viral infections.
Kevin Mulleady and Jason Aryeh attempted to back a slate of candidates for the Phoenixus Board of Directors but failed as shareholders overwhelmingly supported the current board.
The WHO panel recommends adopting global standards, giving structure to prevent the unscrupulous, inequitable, and possibly dangerous uses of CRISPR technology.
A former CEO of Vyera and other activist investors are pushing a slate of new company directors who would steer control of Phoenixus and Vyera away from Shkreli.
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
Sana Biotechnology, a gene and cell therapy hybrid whose mission is to create and deliver engineered cells as medicines for patients, puts the “I” first in Inclusion, Diversity and Equity (IDE).
This week’s announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech’s advisory board.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES